Harbour Biomed is a technology company.
Harbour Biomed has raised $100.0M across 1 funding round.
Key people at Harbour Biomed.
Harbour Biomed has raised $100.0M in total across 1 funding round.
Harbour BioMed is a global biopharmaceutical company focused on discovering, developing, and commercializing novel antibody therapeutics, primarily in oncology and immunology.[1][2][5] It builds proprietary technology platforms like Harbour Mice® for generating fully human monoclonal antibodies in H2L2 and HCAb formats, HBICE® for immune cell engagers targeting tumors, and single B cell cloning integrated with AI tools such as the Hu-mAtrIx™ generative AI HCAb model.[1][2][3] These platforms serve pharmaceutical partners, academic institutions, and its own pipeline, solving unmet needs in antibody discovery by accelerating lead generation to ~4 months (vs. industry 9 months), enabling bispecifics, and improving developability for next-gen biologics.[1][3] The company operates through Harbour Therapeutics for internal assets and Nona Biosciences for open-access tech licensing, with a portfolio including 5 clinical-stage compounds, over 200 preclinical candidates, and at least 6 antibodies in human trials from its platforms.[2][5][6] Growth momentum includes recent AI launches and partnerships with over 40 entities, driving "Healthy life · Breakthrough Medicines."[2][5]
Harbour BioMed was established in 2016, building a robust pipeline in oncology and immunology from the start.[4][6] It leverages exclusive global rights to Harbour Mice® platforms, engineered for high-quality, diverse fully human antibodies via in vivo maturation.[1][5] Key evolution includes acquiring Berkeley Lights’ Beacon® optofluidic tech in early 2019 for single B cell cloning, enhancing discovery efficiency, and launching business units like Nona Biosciences for tech access.[1][2][4] Pivotal moments feature partnerships with global academics and pharmas, co-developments like biosimilars (e.g., Binocrit®, bevacizumab), and clinical assets such as anti-IP10 antibody Eldelumab, yielding 5 in-licensed clinical compounds and rapid internal NextGen projects.[2][5] By 2025, it introduced the first fully human generative AI HCAb model, marking a shift to AI-driven innovation.[3]
Harbour BioMed rides the next-gen biologics wave, emphasizing AI-augmented antibody discovery amid rising demand for oncology/immunology therapies where traditional methods fall short on speed and specificity.[3][5] Timing aligns with AI-biotech convergence (e.g., 2025 HCAb model launch) and bispecific/multi-specific boom, fueled by market forces like patent cliffs on blockbusters and need for tumor microenvironment engagers.[1][2][3] It influences the ecosystem by licensing platforms to 40+ companies/academics, accelerating 200+ candidates to preclinical/clinical stages, and bridging China-global innovation via HKEX listing (02142) and sites in Shanghai, Rotterdam, Cambridge.[2][5] This democratizes high-quality human antibodies, reducing reliance on murine models and boosting efficiency in a $200B+ biologics market.
Harbour BioMed is poised to lead AI-powered antibody innovation, with its self-evolving platforms driving more clinical wins from its 200+ preclinical pool and expanding HBICE®/HBICA™ applications.[3][5] Trends like generative AI in drug design, cross-species binders, and multi-specifics will shape its path, potentially yielding breakthrough approvals in hard-to-treat cancers/inflammations. Influence may evolve via deeper pharmas partnerships and Nona's open model, amplifying global access while Harbour Therapeutics advances internal assets—positioning it as a transformative force from discovery to "Healthy life · Breakthrough Medicines."[2]
Key people at Harbour Biomed.
Harbour Biomed has raised $100.0M in total across 1 funding round.
Harbour Biomed's investors include OrbiMed.
Harbour Biomed has raised $100.0M across 1 funding round. Most recently, it raised $100.0M Series C in July 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2020 | $100.0M Series C | OrbiMed |
